公开(公告)号：US20210322569A1

公开(公告)日：2021-10-21

申请号：US17354514

申请日：2021-06-22

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  THE UNIVERSITY OF KANSAS

Inventor： Steven R. BUCHMAN ,  Mark COHEN ,  Alexis DONNEYS ,  Noah NELSON ,  Laird FORREST ,  Ti ZHANG ,  Qiuhong YANG

IPC: A61K47/69 ,  A61K9/51 ,  A61L27/50 ,  A61K47/61 ,  A61P19/00 ,  A61P19/08 ,  A61K31/16 ,  A61L27/20 ,  A61L27/54 ,  A61L27/58

Abstract: The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

公开(公告)号：US20200101132A1

公开(公告)日：2020-04-02

申请号：US16444829

申请日：2019-06-18

Applicant: The University of Kansas

Inventor： Peter S. N. Rowe ,  Aline Martin ,  Nicolae Valentin David ,  M. Laird Forrest ,  Kenneth Ryan Moulder ,  Shuang Cai ,  Daniel J. Aires

IPC: A61K38/16 ,  A61K9/00 ,  A61K9/107 ,  A61K9/127 ,  A61K8/64 ,  A61Q7/00 ,  A61K8/14 ,  A61K45/06 ,  A61K31/506 ,  A61K31/58 ,  A61K47/10 ,  A61K47/69

Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.

公开(公告)号：US20190314554A1

公开(公告)日：2019-10-17

申请号：US16428534

申请日：2019-05-31

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Michael DETAMORE ,  Emily BECK ,  Stevin GEHRKE ,  Cory BERKLAND

IPC: A61L27/48 ,  A61L27/38 ,  A61L27/50 ,  A61L27/20 ,  A61L27/52 ,  A61L27/54

Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.

公开(公告)号：US10254290B2

公开(公告)日：2019-04-09

申请号：US15450716

申请日：2017-03-06

Applicant: The University of Kansas

Inventor： Mark T. Fisher ,  Subhashchandra Naik

IPC: G01N33/68 ,  G01N33/543 ,  G01N21/65 ,  C12Q1/32

Abstract: A device for studying protein conformation transformation can include a macroscopic substrate, and chaperonin proteins bound to the substrate, each chaperonin protein being capable of binding to a protein of interest during or after undergoing protein conformation transformation. The device may also include the proteins of interest bound to the substrate, where the substrate is included in a label-free assay system. A method of studying protein conformation transformation can include: providing a macroscopic substrate bound with the chaperonin protein and immersing the chaperonin protein in a study composition having the protein of interest, or include providing a macroscopic substrate bound with the protein of interest; and immersing the protein in a study composition having the chaperonin. Such a method can be done with and without a potential stabilizer in order to determine whether the potential stabilizer stabilizes the protein of interest.

公开(公告)号：US10214680B2

公开(公告)日：2019-02-26

申请号：US15226525

申请日：2016-08-02

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Reza Barati Ghahfarokhi

IPC: C09K8/594 ,  C09K8/70 ,  E21B43/16 ,  E21B43/26

Abstract: Polyelectrolyte nanoparticles are generated to stabilize foam for use in enhanced oil recovery. Stability is further enhanced by optimizing pH and a ratio of polycationic and polyanioinic materials, resulting in stronger and longer lasting foams in the presence of crude oil. Use of these nanoparticles results in negligible damage to formation permeability.

公开(公告)号：US20190000858A1

公开(公告)日：2019-01-03

申请号：US15746043

申请日：2016-07-22

Applicant: YALE UNIVERSITY ,  THE UNIVERSITY OF KANSAS

Inventor： Joseph N. CONTESSA ,  Jennifer E. GOLDEN ,  Daniel P. FLAHERTY

IPC: A61K31/5377 ,  C07D277/46 ,  C07D417/12 ,  C07D295/155 ,  C07D295/192 ,  C07D277/82 ,  A61K31/427 ,  A61K31/454 ,  A61K31/402 ,  A61K31/426 ,  A61P35/00 ,  A61K45/06

Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with N-linked glycosylation in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound of the invention.

公开(公告)号：US20180282314A1

公开(公告)日：2018-10-04

申请号：US15940152

申请日：2018-03-29

Applicant: The University of Kansas

Inventor： Blake R. Peterson

IPC: C07D407/12 ,  A61P35/00 ,  G01N33/58

CPC classification number: C07D407/12 ,  A61P35/00 ,  G01N33/582

Abstract: A compound can be a fluorescent taxane derivative having a structure of Formula 1, salt, stereoisomer, tautomer, polymorph, or solvate thereof. Formula 1 can be defined as: L, L-NH, or L-NH—C═O is a linker; and R is a substituent, where —OH, —O−, —NH2, and NH—CH3 are examples. Examples of linkers can include glycine, beta-alanine, gamma-aminobutyric acid (GABA). Pharmaceutical compositions can include the compound and a pharmaceutically acceptable carrier, and may be configured for intravenous injection. The fluorescent taxane derivative can be used to treat cancer and non-cancer diseases. The fluorescent taxane derivative can be used to monitor cellular efflux and determine whether a cell will efflux paclitaxel.

公开(公告)号：US09994556B2

公开(公告)日：2018-06-12

申请号：US15318351

申请日：2015-06-12

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Jinbo Zhao ,  Huiping Zhao ,  Brian S. J. Blagg

IPC: C07D405/14 ,  C07D401/12

CPC classification number: C07D405/14 ,  C07D401/12

Abstract: Provided herein are compounds of the formulas: which are 90-kDa heat shock protein inhibitors. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including cancer, e.g., cancers of the breast, the prostate, and the head & neck.

公开(公告)号：US20180158663A1

公开(公告)日：2018-06-07

申请号：US15832016

申请日：2017-12-05

Applicant: The University of Kansas

Inventor： Craig E. Lunte ,  Ryan Tyler Johnson ,  Nhan To ,  Susan M. Lunte ,  Damon Osbourn

IPC: H01J49/16 ,  G01N30/72 ,  H01J49/04 ,  G01N27/447

CPC classification number: H01J49/167 ,  G01N27/44713 ,  G01N27/4473 ,  G01N30/7233 ,  H01J49/0431

Abstract: Provided herein are capillaries for use in an electrophoretic separations. The capillaries can comprise an elongated tubular wall defining a path for fluid flow from an inlet to a tapered outlet; and a decoupler junction positioned within the elongated tubular wall upstream of the tapered outlet. The decoupler junction can comprise a plurality of microchannels penetrating through the elongated tubular wall and an ion-permeable polymer coating the plurality of microchannels. Also provided are sheathless interfaces for coupling capillary electrophoresis (CE) with mass spectrometry that employ these capillaries.

公开(公告)号：US20170218022A1

公开(公告)日：2017-08-03

申请号：US15480120

申请日：2017-04-05

Applicant: The University of Kansas

Inventor： Blake R. Peterson

IPC: C07K7/08 ,  C07K16/32 ,  C07K16/28 ,  C07K19/00 ,  C07K16/46

CPC classification number: C07K7/08 ,  A61K47/554 ,  A61K47/65 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/06 ,  C07K2319/74

Abstract: A peptide can have a sequence of one of SEQ ID NOs: 78-91. A conformationally-constrained kinked peptide includes: a conformationally-constraining portion and a kinked portion linked to the conformationally-constraining portion that conformationally constrains the kinked portion having a peptide sequence of one of SEQ NOs: 78-97. A cell-targeting compound can include a conformationally-constrained kinked peptide having a peptide sequence of one of SEQ ID NOs: 78-97. The peptide sequence can be one of SEQ ID NOs: 78-97, or 78-91, or 92-97. A cell-targeting compound can include a conformationally-constrained kinked peptide linked to a branched linker with one branch arm linked to a specific targeting moiety and one branch ann linked to a general targeting moiety. The specific targeting moiety can be an antibody. The general targeting moiety can be a lipid or cholesterol derivative.